by Fabio Giuseppe Carlo Carisio for VT Europe
About One Nucleus: Established in 1997, One Nucleus is an award winning not-for-profit Life Sciences & Healthcare membership organisation centred on the Greater London-Cambridge-East of England corridor. Headquartered in Cambridge, at the heart of Europe’s largest Life Sciences & Healthcare cluster, we support those institutions, companies and individuals undertaking activity in or with the above region.
In that same area, AstraZeneca has developed a partnership with GSK, or GlaxoSmithKline, the other London vaccine multinational controlled by the same US investment funds and convicted several times in the courts. Their mission was to develop tests to detect the infected in the United Kingdom, where there has actually been a boom in positives to the SARS-Cov-2 virus, although in a very high percentage asymptomatic as in other European nations and especially in Italy.
From February 27, 2020, one of the most important multinational companies specialized in diagnostics, laboratories and clinical trials to test the possible danger of drugs and facilitate their marketing, Cerba Healtcare International in Paris, joined One Nucleus and started sharing the answer. against the SARS-Cov-2 pandemic not only in England and France but also in Italy, Belgium and China.
ADULTERATED SWABS IN TANZANIA
Even an elementary school child would well understand that these mysterious interconnections, because they are covered by the privacy laws and international patents of the pharmaceutical industries, represent a sensational conflict of interest between those who have to make the lucrative vaccines against Covid-19, who must test them as independent third party and who must perform and analyze the swabs to highlight to the rulers, politicians and the international scientific community the seriousness of the spread of the infections and therefore the restrictive measures necessary to contain the pandemic.
This Big Pharma cartel in which the ring of economic interests closes, obviously for the good of shareholders more than humanity, is even more suspicious if it is noted that most of the new infections in Italy, albeit at 95% asymptomatic as claimed by many world-famous virologists such as Professor Giorgio Palù, academic in Padua and Philadelphia, have emerged in Lombardy and Piedmont precisely where the Italian branch of Cerba operates which in the last three years, from 2017 to October 2019, has acquired the most important laboratory chains in northern Italy as if in a crystal ball he had intuited the future business deriving from the epidemic of the new Coronavirus strain.
“To think badly makes you sin but often you guess” said the Italian Prime Minister Giulio Andreotti several times, making this aphorism very famous. Among the first to think badly was John Pombe Magufuli, the very Christian president of Tanzania (reconfirmed at the head of the nation since the elections at the end of October), who had the swabs received as a gift from the African section of the World Health Organization tested and found positive Covid-19 a goat, a quail and even a papaya. The purchasing manager of the Ministry of Health was fired on the spot and the story ended up in many global counter-information media curious to know who had produced those swabs that someone suspected were “used” and therefore already positive.
Gospa News revealed that they came from a donation from the Jack Ma Foundation, a self-styled Chinese philanthropic organization created by the owner of Alibaba, the main Asian E-commerce platform that was enriched like Amazon during the period of lockdowns in China and other Eastern countries. thanks to the closure of retail and wholesale stores.
MYSTERIES ON THE VIRAL CHARGE OF ASYMPTOMATICS
Far from suspecting that the test analysis process of a prominent diagnostics giant such as Cerba Helath International may be vitiated by actual conflicts of interest, however, a necessary premise must be made on the uncertainty and variability of the mechanism itself.
As specified in the latest reports on the methods of gene amplification carried out in the laboratories during the analysis process of the PCR rhino-pharyngeal swabs, their reliability depends: an excessive amplification, in fact, as explained by the virologist Palù, can detect the positivity of any microbe. While it was the Spallanzani National Institute of Infectious Diseases in Rome that highlighted the lack of antigen tests capable of “distinguishing seasonal flu from the Covid-19 coronavirus” thus highlighting gigantic doubts about the reliability of the swabs.
Despite so, one of the leading researchers of Cerba Italia pointed out the impending gravity of the “new wave” of academia on the mainstream media, contrary to what is claimed by much more illustrious virologists. “The viral load is rising to very high levels, that is the number of copies of genetic material of the new coronavirus present in a milliliter of biological material taken with the swab, so much so that” in 80% of positive cases it is now over one million” virologist Francesco Broccolo, from the Milan Bicocca University and director of the Cerba laboratory in Milan, told ANSA,” wrote the Italian press agency.
“Very often – he added – the viral load is even higher, up to billions in asymptomatic or symptomatic subjects between 30 and 60 years old”. The data indicates that the infections are recent: “a very high viral load – Broccolo noted – is an indication of a new active infection”. That is, it indicates that “the infection is recent and primary, that is, it has not persisted for months”.
These statements aroused our perplexity given that Professor Palù, president of the European Society of Virology for 7 years, had given an interview to TV7 claiming that there was still no possibility to verify the actual viral load in asymptomatic patients. Palù, interviewed by Gospa News regarding Broccolo’s statements, confirmed that “there is still no internationally validated viral load test”.
“The emergency to stop the infections is faced with swabs. Antibody tests on blood have important, different and non-overlapping uses. Too many play on the misunderstanding “: the statement by Stefano Massaro, CEO of Cerba HealtCare Italia, the company specialized in laboratory analysis willing to commit resources and molecular biologists in the battle against the virus, as reported by the company’s official website.
“Our Scientific Management has clear ideas – affirms the CEO of Cerba HealthCare Stefano Massaro – and it is our task to convey correct communication”. From the initial moment of the COVID 19 emergency, the tests used and released and with which the positives are currently counted are molecular tests for the search for SARS-COV2 viral RNA on nasopharyngeal swab. This is a direct research: if the virus is present in the mucous membranes, the test is positive and the diagnosis is certain of an infection in progress, regardless of the symptoms.
This led us to investigate Cerba by discovering its “altars” with the Big Pharma AstraZeneca, Johonson & Johnson, but also GSK that we will now highlight in every detail starting from Belgium where the task force formed by vaccine companies and laboratories first came into action. diagnostics.
BELGIUM: TASK FORCE AND BOOM OF INFECTIONS
First of all, it should be noted that the European nations in which Cerba operates are among those at the top in the explosion of autumn infections. Among the countries most affected are in fact France, where the diagnostic laboratory has its headquarters in Paris and collaborates with the national government, Italy, which we will talk about more specifically later, and Luxembourg where it has an important headquarters the diagnostics multinational that presents itself as a European leader in the sector but operates in 16 countries through various partnerships (including China and Africa).
But the most striking case is represented by Belgium. «Cerba Research Proud to be part of Government Task Force in combat against Covid-19. The Belgian Taskforce to combat Covid-19 has taken off! Cerba Research and sister company, CRI, have engaged to be a vital part of the government-led consortium, alongside PPD, JnJ, GSK, Biogazelle, UCB ULiège, Sciensano, ThermoFisher, UgenTec and MIPS. Together, we will work to upscale Covid-19 testing in Belgium».The map of infections in Europe in recent weeks has seen Belgium in first place
This is what was already read in March on the website of the same group, citing among the partners GlaxoSmithKline, managed by a non-executive director of Microsoft Corporation and financed in various research on vaccines by the foundation of Bill Gates, but also Johnson & Johnson, another pharmaceutical giant with various judicial convictions, which is a partner of the Eco Health Alliance of New York.
EHA a global non-profit organization for environmental health that financed the EPT-PREDICT projects, commissioned by the Barack Obama US administration and funded by the American government agency USAID, operational tool of the Central Intelligence Agency, on the extremely dangerous experiments on bat superviruses in Wuhan with the SARS-1 genotype infected with HIV, the pathogen of AIDS.
They are joined by PPD, a contract research organization in the Pharmaceutical and Biotechnology sector based in Wilmington, North Carolina (US) that deals with drug development and laboratory analysis.
«Led by Federal Minister Philippe De Backer, the members of the task force will work to increase testing against Covid-19, an important tool in tackling the further spread of the virus, in order to flatten the curve. Cerba Research, the central lab division, with its Headquarters in Ghent, Belgium, is providing the logistical support and organization for this project and this way plays a pivotal role in the delivery of patient samples to pharma and academia for Covid-19 testing».
Mario Papillon, CEO of Cerba Research, stated: «The Covid-19 pandemic is heavily impacting our society, and we must work together to overcome the situation. Cerba Research is proud to join efforts with the Belgian government, Biogazelle, GSK, JnJ, UCB and PPD to significantly improve testing capabilities to our elderly living in nursing homes».
As we know in the country of the Flemings there has been a boom in infections that has caused a growing alarm for the European Union, which immediately committed itself to purchasing future vaccines from AstroZeneca-Oxford and GSK-Sanofi. A similar situation has arisen in England after the pact of steel between two of the vaccine giants.
«As part of the UK Government’s announcement of a new five pillar plan to boost testing for COVID-19, GSK, AstraZeneca and the University of Cambridge have formed a joint collaboration to take action to support this national effort – reported already on Mrach the GSK official website – A new testing laboratory will be set up by GSK, AstraZeneca and Cambridge at the University’s Anne McLaren laboratory. This facility will be used for high throughput screening for COVID-19 testing and to explore the use of alternative chemical reagents for test kits in order to help overcome current supply shortages».
«Alongside this new testing facility, GSK and AstraZeneca are working together to provide process optimisation support to the UK national testing centres in Milton Keynes, Alderley Park and Glasgow for COVID-19, providing expertise in automation and robotics to help the national testing system to continue to expand capacity over the coming weeks» the London corporation further highlighted.
If GlaxoSmithKline, known for having incorporated the SmithKline which in 1999 paid the then Minister of Health Francesco De Lorenzo before the hepatitis B vaccine was made mandatory in school age in Italy, and AstraZeneca, in turn involved in various scandals and sentenced to large compensation for health fraud in the world, if they did not have these judicial records it would certainly be easier to believe in their good faith and in a truly humanitarian initiative.
But given that these are the same companies that are working on developing vaccines against the SARS-Cov-2 virus, which many scientists and intelligence experts believe to be made in the laboratory, suspicions of conflicts of interest become more legitimate …
CERBA NEXT TO THE BIG PHARMA OF VACCINES
It is therefore not clear why an esteemed multinational such as Cerba Health International wanted to join the Big Pharma cartel as it boasted of having done on February 27, 2020, a few weeks after the outbreak of the epidemic in Wuhan and even before the World Health Organization decreed a pandemic status on the entire planet (11 March).
«Cerba Research has become the latest Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs both of the Partner and the interests of One Nucleus members» you can read on the official websites of both companies.
Sofie Vandevyver, Head of Business Operations & Marketing, Cerba Research declared: «We are proud of having formed this exciting new alliance with One Nucleus. We are confident this collaboration will allow us to bring people together and drive our leadership position within the field of precision medicine».On Helix, the event organized last July by One Nucleus of which AstraZeneca and J&J are partners together with Cerba Health International
Tony Jones, CEO of One Nucleus expands further: «One Nucleus is committed to connecting the life science community and showcasing the expertise of our members that will support other businesses in the sector. We are excited to welcome Cerba Research as our newest partner and it is only by building these relationships that we can bring valuable insights into our network to drive the discussion that will move healthcare innovations forward».
«Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials» the official statement still reads in reference to those fundamental tests, especially for the official approval of a vaccine.Cerba Health International’s press release on joining One Nucleus
«With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world».
«From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas».
The diagnostics multinational in Paris thus becomes the missing link in the Big Pharma business chain: from infection screening it can provide assistance in drug trials (top secret for industrial patent reasons) to their marketing… (read more)
Fabio Giuseppe Carlo Carisio
© COPYRIGHT GOSPA NEWS for VETERANS TODAY only
no reproduction without authorization – Versione originale in Italiano
Fabio is Director and Editor of Gospa News; a Christian Information Journal.
Fabio Giuseppe Carlo Carisio, born on 24/2/1967 in Borgosesia, started working as a reporter when he was only 19 years old in the alpine area of Valsesia, Piedmont, his birth region in Italy. After studying literature and history at the Catholic University of the Sacred Heart in Milan, he became deputy director of a local newspaper and specialized in judicial reporting.
For about 15 years he is a correspondent from Northern Italy for the Italian newspapers Libero and Il Giornale, also writing important revelations on the Ustica massacre, a report on Freemasonry and organized crime.
With independent investigations, he collaborates with Carabinieri and Guardia di Finanza in important investigations that conclude with the arrest of Camorra entrepreneurs or corrupt politicians.
In July 2018 he found the counter-information web media Gospa News focused on geopolitics, terrorism, Middle East, and military intelligence. He is a correspondent from Italy for the French news site Reseau International.
He worked for many years for the magazine Art & Wine as an art critic and curator.